Halozyme Therapeutics Incorporated (HALO)

Thank you. Feel free to write to Halozyme and share the message (you have my permission to copy and paste)

Indeed!

To your point, 30% of SpaceX is targeted for retail.

Great Job….

Halozyme’s new CFO, “Mr. Snellgrove led investor relations at Johnson & Johnson, where he oversaw global investor engagement and helped strengthen corporate messaging, analyst relationships, and market performance.”
Welcome aboard! Halzoyme is in need of a major shake up in its IR. One of the biggest contributors to extremely low PEG and forward PE valuations has been an inability to attract non-institutional investors. Prices in modern markets are determined by the marginal buyers. Halozyme is almost 100% institutionally owned.
I hope you and Helen take the time to appear on CNBC, bloomberg, investor YouTube channels and Podcasts.
It would also help a lot if you buy some shares yourself in the open markets.
We look forward to seeing a meaningful improvement in Halozyme’s valuations under your leadership.
https://halozyme.com/leadership/darren-snellgrove/

https://www.wealthenginepro.com/insights/the-case-for-halozyme

Forgot Roche also.

Forgot roche in that post.

Lots of good stuff happening to halo. Jnj and Argx were up big today. Easily going over 100 soon.

Considering the bloodbath in all the indices today to finish at down .1% shows not much selling to jump into space x ipo from the institutions....lol...imao...r

News on argenx... argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise and pipeline, with CFO Karl Gubitz stressing the company has evolved into a fully integrated global biotech.

The company is targeting 50,000 patients on treatment by 2030, up from 19,000 at the end of last year, and aims to reach 10 labeled indications and five new Phase III molecules by decade’s end. (not breaking out the subset figures on SC) https://finance.yahoo.com/sectors/healthcare/articles/argenx-touts-vyvgart-growth-50-100223333.html ...r

This is the "summation" of Ms Grez testimony that HALO will use to in its appeal to the Patent Director case in hammering home its main legal focal point that MCI and MSD are both RPI's thus spoiling the original PGR request that was sought... https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00052%2F80 ....imao...r

MERCK is a corrupt company. In their own litigation against John Hopkins University regarding keytruda, Merck named both the subsidiary and the parent company as real parties of interest. (RPI).

So in regards to patent case PGR2025-00052...testimony of Kelly Grez corporate sec...The attorney for HALO produced 7 SEC documents that she signed off on that has names of employees of MSD LLC but were submitted as employees of Merck inc. This nebulous "dual role" claim that Merck employs is being exposed as problematic...some of them weren't even Merck Inc employees... this issue comes up at the very end of the deposition...It was nearly 9 hrs long...interesting that Ms Grez had a dual role herself but no separate office/desk/phone/ or email to delineate each of her capacities at any given time.... https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00052%2F1225 ...r

The key question is how large VYVGART sales could become if myositis and Sjögren's disease are eventually approved, because Halozyme earns a royalty on VYVGART Hytrulo sales that use ENHANZE.

Here is a reasonable framework:

Scenario Annual VYVGART Sales Halozyme Royalty (approx. 4%–6%)
Current approved indications continue growing $7 billion $280M–$420M
One major new indication succeeds $8–10 billion $320M–$600M
Both myositis and Sjögren's succeed and become large products $10–12+ billion $400M–$720M+

Halozyme's investor presentation cited analyst projections of approximately $7 billion in VYVGART sales by 2028 from just the currently approved indications (gMG and CIDP), and highlighted myositis and Sjögren's as important future growth opportunities. Halozyme also noted that it receives "mid-single-digit royalties" on VYVGART Hytrulo sales.

For perspective:

VYVGART generated $4.2 billion of sales in 2025, up from $2.2 billion in 2024.
Argenx continues to advance studies in myositis and Sjögren's disease and has reported encouraging data in both areas.
Halozyme's presentation places myositis in the 2026–2027 wave of potential launches and Sjögren's in the 2028–2030 wave.
What could it mean specifically for Halozyme?

If VYVGART reaches the projected $7 billion by 2028, Halozyme could be receiving roughly $300–$400 million annually from VYVGART alone, depending on the exact royalty rate.

If myositis and Sjögren's both become approved and commercially successful, an additional $3–5 billion in annual VYVGART sales would not be an unreasonable long-term possibility. At a mid-single-digit royalty, that could add another $120–$300 million per year to Halozyme's royalty stream.

Timing

Based on current development timelines:

Myositis: potential approval opportunity around 2027–2028
Sjögren's disease: more likely 2028–2030
Peak sales contribution would probably occur several years after approval as physicians adopt the drug and reimbursement expands.

So when investors pushed Halozyme higher on the argenx news, they were likely thinking not about a few million dollars of extra royalties, but about the possibility that VYVGART eventually becomes a $10+ billion franchise, which could translate into $500 million to $700+ million of annual royalty revenue for Halozyme over the next decade. That is a very meaningful amount for Halozyme's earnings power

The most likely reason Halozyme (NASDAQ: HALO) jumped today is that its partner argenx released new positive data on VYVGART (efgartigimod) at the EULAR 2026 medical meeting. The data showed:

Sustained, clinically meaningful benefits in patients with myositis.
Continued positive results in Sjögren's disease.
A consistent safety profile across multiple autoimmune diseases.

Why this matters for Halozyme:

VYVGART Hytrulo is a subcutaneous version of argenx's blockbuster drug that uses Halozyme's ENHANZE drug-delivery technology. Halozyme receives royalties on sales of products that use ENHANZE.

Investors are likely looking beyond the current approved indications (generalized myasthenia gravis and CIDP) and focusing on the possibility that:

Myositis could become a future approved indication.
Sjögren's disease could become another large market opportunity.
Every new approved indication could increase VYVGART Hytrulo sales and therefore increase Halozyme's royalty revenue.

For Halozyme shareholders, the key takeaway is not today's data itself, but the possibility that VYVGART continues expanding into additional autoimmune diseases. Since VYVGART is already one of Halozyme's largest royalty-generating products, successful expansion could translate into years of additional royalty growth.

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology .Benchmark maintained its Buy rating and $90 price target on Halozyme, with the firm noting the stock has potential for gains this year.

It may have been at least partially due to “Benchmark maintains Halozyme Therapeutics $90 target”

I don’t want to be a wet blanket because I really would like this to mean something, but like I said in previous responses, if today is due to a serious buyer, when they’re done buying, the trading will go back to the manipulative traders and short sellers. I hope I am wrong.

Nice day. Plenty of runway left. 

The close will be interesting. I don’t think hugely telling based on other price action I’m seeing, but will be interesting to see..

Knock on wood this action holds!! Nice start!

Hope so. We’ll know he’ll get a lot of options and restricted stock, we’ll see if he assist in getting this share price moving again!

Maybe he will buy some shares in the open market right after he starts! That will send strong signal.

Likely based on analysts forecasts.

As well, I don’t really halo guiding to 39% eps growth over next 5 years? I don’t recall seeing any guide past 2028, only a guide to Rev in 2035 for new platform?

Let’s see what New CFO can bring to party. Soon. Hope he has a magic touch. I asked for a high power cfo, as the rest of team appears more technically astute (which is great), but it’s not generating shareholder value for a long while.we got the huge spike when Helen killed the pancreatic and insulin programs (that coupled with daralex sc going into production). That was like 15 to 50 in under 2 years - back in like ‘19. I hope we have 1 more run like that in us.

EPS Next Y $9.93
EPS growth this year 95.41%
EPS growth next 5 years 39.10%
Gross Margin 76.93%
All this trading at a forward PE of 6.66 and PEG of 0.17
https://finviz.com/stock?t=HALO&ty=c&ta=1&p=d

It is not only irresponsible for the insider not to buy shares, it is also idiotic to pass up on such amazing value and growth.

EPS Next Y $9.93EPS growth this year 95.41%EPS growth next 5 years 39.10%
Gross Margin 76.93%
All this trading at a forward PE of 6.66 and PEG of 0.17
It is not only irresponsible for the insider not to buy shares, it is also idiotic to pass up on such amazing value and growth.

XBI is down 3.4%.

And now a nasty day. The trading pattern is super Ugly. I bet they halo bought yesterday, and can’t hold have the fire power to hold off the institutions that despise halo business model..

A pretty decent day. I suspect Halo is doing some buybacks, based on price action (which was pretty good) coupled with volume. I just hope they have some ammo and staying power to fight these institutions who don’t care for halo like Goldman and JP.

Director Squires denied institution of Merck’s PGR2025-00087
https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00087%2F22

https://portal.unifiedpatents.com/ptab/case/PGR2025-00087

Why This Is Significant for Halozyme
1. It stops Merck’s PGR campaign at 14.PGR2025-00087 targeted a 15th Halozyme patent. That patent now retains its full presumption of validity — PTAB will not adjudicate its validity under the PGR track. Merck cannot refile a PGR against it (the 9-month window has almost certainly passed).
2. It signals Director Squires is not rubber-stamping Merck’s entire campaign.The Director instituted 14 PGRs and now denied the 15th on discretionary grounds. This is the first signal that the Director is exercising independent judgment in Merck’s favor is not unconditional. That’s a meaningful institutional signal for Halozyme’s Director Review petition on the termination denial.
3. The 15th patent joins the 3 PGR-ineligible patents as PTAB-protected assets.Halozyme now has 4 patents that have survived the PGR track entirely — 3 PGR-ineligible patents plus the newly protected PGR2025-00087 target. Merck can still file an IPR against the PGR2025-00087 patent (IPR has a different eligibility window), but the §325(d) prior art overlap argument now applies strongly.
4. The §325(d) argument strengthens the 3 IPR defense.The Director’s discretionary denial of PGR2025-00087 on §325(d)/non-merits grounds directly supports Halozyme’s argument that IPR2026-00312/313/314 should also be denied on §325(d) grounds — same prior art, same specification, same arguments already fully litigated in 14 prior proceedings.

You can claim to be long and not a permabear all you want, but your posts over the years suggest otherwise.
You were poopooing halozyme in teens, $20’s, $30’s…. You certainly can’t deny the chart I posted (my last post) for halozyme’s performance. You were dead wrong last time Halzoyme corrected (2023) from an all time high in $50’s to $35. And you are dead wrong now. I will remind you of this when we are back in $80’a and beyond just like I’m reminding of you 2023 and many other time frames before that.
Unlike you, I say it like I see it whether it is positive or negative, bull or bear. I was a big critic of Helen when she wanted to buy Evotec. I even posted here that she should course correct or step down. I have also been critical of the lack of IR and storytelling which has lead to a subpar multiple.
My AI assisted handicapping of Halzoyme winning the “termination” against Merck’s PGR’s turned out wrong. So I am not always right with everything. But unlike you, I’m not a permabear or perma-anything.

I have not been spreading any misinformation and I’m not a permabear. I’ve just said that there haven’t been good reasons to buy halo in the $60s and $70s. Everything else you say is typical of inexperienced and not very knowledgeable investors. I hope the other posters can recognize that. I am not judging you. I am just pointing out that you have been wrong over and over in the past several years. My average in Halo is $6. The last shares I bought were at $14, which is where I believe Helen bought shares for the last time. I’m not selling but I haven’t bought in a very long time.

Attached is an all-time chart of Halozyme compared to Nasadaq and XBI. As you can see, Halozyme has out performed both of them handsomely. So you are dead wrong! Of course, anyone can CHERRY PICK a particular time frame and claim that not just halozyme but even NVDA, APPLE, alphabet, Lilly have underperform Nasada or other benchmarks. 
You have been a permabear on this board spreading misinformation and fear when halozyme was trading in single digits, teens, $20’s, 30’s, $40’s…. You are the one we hope readers have not been taking advice from.
In terms of the drop from $82 to $60’s, this is not the first time halozyme has had a correction and it won’t be the last. Some of the most successful investments (Amazon, Apple, NVIDIA, lilly) have had correction and some of those corrections took a long time to recover from.
Overall, your comments are comical. You said the same nonesense in 2023 when halozyme had a correction from what was back then an all time high in 50’s down to $35. It then went from $35 all the way to $80’s with you poopooing it every step of the way.
Next time do some fact checking and have some self reflection before you judge others!

A third way to react is to realize that you have been wrong about halo for several years now. Buying and encouraging posters to buy at all prices including the “dip” from $82 hasn’t exactly been good advice, to put it mildly, especially since the biotech sector and the market in general has offered tremendous opportunities. Halo has underperformed the Spy, qqq, xbi, and hundreds of individual stocks. I just hope not too many people have followed your poor advice. Do you ever wonder that you may be wrong and maybe the most influential analysts, like JPM’s, are right?

Good point..

Everything you said is true. There are 2 ways to react to these facts. 1) get frustrated and walk away, 2) accumulate more knowing that markets can be irrational but not forever so. 

We’re 6 mos into a year that has no acquisition overhang, 100% eps growth, and crickets. Sell off at end of every single day. Watch every single day this week, bump during day and horrible close.

When a $1b buyback - on a $8b stock can’t break that trend, it’s not good.

We’re in rough patch, sell off at end of every trading session, every single session. If I was trading this, - I’d buy at open and sell at 3.30pm eastern.. every day. It’s simple.

Thanks. We can only hope.

I do. Listen to JNJ’s last quarterly call to get a sense of the new CFO’s storytelling abilities.
The bar is set so low with the current IR director at halozyme that I think it should be easy to see significant improvement.
The current IR director does not even return phone calls or emails. She came from Antares, a sub-biilion market cap company that Halo bought in 2022. She is out of her league! 

This is directed to biotechinvestor. I know you have been for a long time pushing for a meaningful retail contingent to get involved in investing with HALO. Right now, and for a long time, unless there is a real buyer acquiring shares, the stock is controlled by manipulative traders and short sellers. My question to you is, do you think the new CFO, who will also be involved in investor relations, will be able to use his Wall Street connections to improve the trading of HALO stock? I mean this trading of the stock of such a quality company is a joke.

The DCF work suggests Halozyme is trading at a steep discount, with the stock at $68.32 compared with an estimated future cash flow value of $345.55, which points to a very wide gap. If that gap narrows, it could be because the price moves or because the assumptions change.

After reading the termination denial motion by PTAB, here is what Claude has to say:
“ The Johns Hopkins prior listings — Not addressed.Remarkably, the panel does not appear to have addressed the prior KEYTRUDA IPR listings of MCI as RPI in nine prior proceedings. This is the most conspicuous absence in the entire opinion and Halozyme’s strongest argument for Director Review.
The panel’s analysis is vulnerable on Director Review on three specific grounds:

Vulnerability 1 — The Hopkins prior listings are unaddressed.The panel’s failure to address the nine prior KEYTRUDA IPR proceedings where MSD’s own lead counsel (Kushan/Sidley) listed MCI as RPI is the most significant gap in the opinion. This is not a minor omission — it is the single most probative piece of evidence in the record and the panel simply doesn’t engage with it. On Director Review, Halozyme will hammer this omission.
Vulnerability 2 — The Tianma new IPR disclosures are unaddressed.The panel also doesn’t address the March 2026 IPRs where Merck felt compelled to add the parent corporate disclosure per Tianma guidance. Again, an unaddressed fact that directly contradicts the panel’s finding that MCI is clearly not an RPI.
Vulnerability 3 — Ms. Grez’s credibility on the confidential record.The panel credited Ms. Grez’s testimony extensively — “we find her testimony credible and generally supportive.” Director Review typically defers to credibility findings. But Ms. Grez’s testimony that she had no knowledge of a common interest agreement between MCI and MSD covering these PGRs, while herself a dual-role MCI officer/MSD employee who authorized officers may sign on behalf of both entities — is a tension the Director could probe.“

Halozyme at minute 3:20

I think it’s clouding more than you think, and less than I do. I don’t think it’s anything large, but I’ve followed this stock for a Long Time.. I of the reasons I was so excited to see a 1. A new cfo. 2. One with big Horsepower.

Maybe if I say this another way, it’ll make more sense. Let’s say we have 100M shares outstanding. We completely stopped buy backs for 5 years. We issued NO obvious News saying we’re issuing new shares. Yet at end of 5 years, we have 120m share outstanding.. my only slight concern is, are the buy backs clouding anything?